These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 3782973)
1. [Clinical and experimental studies on a new intrabronchial infusion therapy of immunopotentiator-OK-432 in lung cancer]. Gose K; Hirota S; Imajo Y; Adachi S; Yonezawa K; Soejima T; Takada Y; Kimura S; Tsubota N Nihon Gan Chiryo Gakkai Shi; 1986 Jul; 21(6):1208-16. PubMed ID: 3782973 [No Abstract] [Full Text] [Related]
2. [The clinical effect of concomitant use of non-specific immunopotentiator OK-432 on primary lung cancer treated with radiation combined with chemotherapy]. Ogawa Y; Kimura S; Imajo Y; Imanaka K; Gose K Nihon Gan Chiryo Gakkai Shi; 1982 Oct; 17(7):1949-56. PubMed ID: 7161555 [No Abstract] [Full Text] [Related]
3. [Induction of the human tumor necrosis factor (h-TNF) by the streptococcal preparation, OK-432--a clinical trial in 10 lung cancer patients with pleural fluid]. Miyai M; Matsuka Y; Tsubota T; Asano K Nihon Gan Chiryo Gakkai Shi; 1986 Jul; 21(6):1285-91. PubMed ID: 3782979 [No Abstract] [Full Text] [Related]
4. [Antitumor activity of neutrophils induced by a nonspecific immunopotentiator OK-432. II. Experimental study using human malignant ascites]. Umemoto T; Saji S; Oonishi A; Kunii Y; Goshima H; Tachibana S; Takao H; Tanemura H; Sakata K Nihon Gan Chiryo Gakkai Shi; 1988 Jul; 23(7):1512-7. PubMed ID: 3183459 [No Abstract] [Full Text] [Related]
5. [The effect of OK-432 in the treatment of primary lung cancer]. Kishimoto T; Okada K Gan To Kagaku Ryoho; 1987 Apr; 14(4):1051-6. PubMed ID: 3494430 [TBL] [Abstract][Full Text] [Related]
6. [Selective intraarterial infusion of OK-432 in advanced malignancies]. Sakamoto K; Ohtsuki S; Hasegawa M; Shimizu T; Sako M; Yuri H; Nishiwaki Y; Yokogawa S Nihon Gan Chiryo Gakkai Shi; 1985 Feb; 20(1):84-93. PubMed ID: 3998574 [No Abstract] [Full Text] [Related]
7. [The Su-polysaccharide skin test in lung cancer]. Harada J; Horiguchi T; Oki K; Miyamoto H; Osada T Gan To Kagaku Ryoho; 1987 Sep; 14(9):2697-702. PubMed ID: 3307634 [TBL] [Abstract][Full Text] [Related]
8. [Clinical studies of long-term administration of OK-432 in patients with gynecologic cancer]. Mano T; Kawamoto K; Miyake T; Torigoe T Nihon Sanka Fujinka Gakkai Zasshi; 1989 Sep; 41(9):1439-45. PubMed ID: 2685142 [TBL] [Abstract][Full Text] [Related]
9. [Immune responses and clinical effects of OK-432 immunotherapy in lung neoplasms]. Watanabe H; Komori Y; Yamada T; Iwa T Nihon Kyobu Geka Gakkai Zasshi; 1979 Apr; 27(4):451-8. PubMed ID: 469305 [No Abstract] [Full Text] [Related]
10. [Immunochemotherapy of resectable lung cancer--a preliminary study on a comparison of the control, levamisole, and OK-432]. Okayasu T; Kashimura Y; Matano J; Kawabata M; Takeoka T; Hashimoto M; Tanabe T Gan To Kagaku Ryoho; 1982 Sep; 9(9):1646-52. PubMed ID: 6764120 [TBL] [Abstract][Full Text] [Related]
11. Clinical value of immunotherapy with the streptococcal preparation OK-432 in non-small cell lung cancer. Watanabe Y; Iwa T J Biol Response Mod; 1987 Apr; 6(2):169-80. PubMed ID: 3585412 [TBL] [Abstract][Full Text] [Related]
13. [Clinical significance of Su-polysaccharide (Su-PS) skin test in patients with primary lung cancer treated with chemotherapy and administration of OK-432, with special reference to the therapeutic effect and prognosis]. Horiuchi M; Sato K; Nakarai I; Shinoda A Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 2):468-74. PubMed ID: 2181937 [TBL] [Abstract][Full Text] [Related]
14. [Effect of endoscopical administration of OK-432 in 4 patients with advanced esophageal or gastric cancer]. Satomi T; Inoue S; Fujita T; Ogawa S; Honda H; Hayashi M Gan No Rinsho; 1989 Mar; 35(4):512-5. PubMed ID: 2541269 [TBL] [Abstract][Full Text] [Related]
15. [Treatment of non-A, non-B hepatitis with immunopotentiator OK-432]. Shimada Y; Hirakawa H; Fukumoto S; Nagaoka S Nihon Rinsho; 1988 Dec; 46(12):2689-702. PubMed ID: 3149343 [No Abstract] [Full Text] [Related]
16. [Oral administration of OK-432 (Picibanil) (7th report). Clinical application: effects on advanced and recurrent cancers]. Nio Y; Ohgaki K; Kan N; Tsuchitani T; Imai S; Okino T; Hori T; Tobe T; Nakamura M; Kodama H Nihon Gan Chiryo Gakkai Shi; 1987 Dec; 22(10):2436-45. PubMed ID: 3449590 [No Abstract] [Full Text] [Related]
17. Histological changes caused by intralesional injection of a streptococcal preparation into bladder cancer. Fujita K Cancer Detect Prev; 1988; 11(3-6):397-403. PubMed ID: 3292046 [TBL] [Abstract][Full Text] [Related]
18. [Intratumoral injection of OK-432 with contrast medium by ultrasonically guided puncture for hepatoma]. Yasuda H; Takada T; Uchiyama K Nihon Igaku Hoshasen Gakkai Zasshi; 1984 Jul; 44(7):992-4. PubMed ID: 6096805 [No Abstract] [Full Text] [Related]
19. [Randomized controlled study of OK-432 in the treatment of cancerous pleurisy]. Urata A; Nishimura M; Ota K Gan To Kagaku Ryoho; 1983 Jun; 10(6):1497-503. PubMed ID: 6409006 [TBL] [Abstract][Full Text] [Related]
20. [Experimental studies on specific active immunotherapy using immune responses of irradiated tumor tissue. 4. Effects of a combined use of a non-specific immunopotentiator, OK-432]. Imanaka K; Ogawa Y; Gose K; Imajo Y; Kimura S Nihon Gan Chiryo Gakkai Shi; 1982 Aug; 17(5):1299-304. PubMed ID: 7153621 [No Abstract] [Full Text] [Related] [Next] [New Search]